Bedel Financial Consulting’s Chemours CC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-180
Closed -$6K 307
2022
Q1
$6K Hold
180
﹤0.01% 741
2021
Q4
$6K Hold
180
﹤0.01% 746
2021
Q3
$5K Hold
180
﹤0.01% 766
2021
Q2
$6K Hold
180
﹤0.01% 743
2021
Q1
$5K Buy
180
+99
+122% +$2.63K ﹤0.01% 735
2020
Q4
$2K Hold
81
﹤0.01% 734
2020
Q3
$2K Hold
81
﹤0.01% 697
2020
Q2
$1K Hold
81
﹤0.01% 722
2020
Q1
$1K Hold
81
﹤0.01% 723
2019
Q4
$1K Hold
81
﹤0.01% 716
2019
Q3
$1K Hold
81
﹤0.01% 694
2019
Q2
$2K Hold
81
﹤0.01% 637
2019
Q1
$3K Sell
81
-409
-83% -$14.9K ﹤0.01% 604
2018
Q4
$14K Buy
490
+4
+0.8% +$127 0.01% 408
2018
Q3
$18K Buy
486
+25
+5% +$1.09K 0.01% 392
2018
Q2
$20K Buy
461
+2
+0.4% +$99 0.01% 376
2018
Q1
$22K Buy
+459
New +$22.9K 0.02% 368

Other funds holding CC

Bedel Financial Consulting's CC Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Chemours (CC) in Q2 2022, closing a stake of 180 shares — an estimated $6K sold.

Bedel Financial Consulting first reported a position in CC in Q1 2018 and held it in 17 quarters. The position peaked at $22K in Q1 2018. 517 funds tracked by Wall St. Rank hold CC as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Chemours position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 180 Chemours shares in Q2 2022, an estimated $6K.
  • Bedel Financial Consulting first reported a position in Chemours in Q1 2018 and held it in 17 quarters.
  • Bedel Financial Consulting's Chemours position peaked at $22K in Q1 2018.
  • 517 funds tracked by Wall St. Rank held Chemours as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.